Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 21,991 matching trials from the live ClinicalTrials.gov search.
Conditions
Cerebral Palsy Infantile, Pre-Term, Motor Delay, Neurodevelopmental Disorders, Autism Spectrum Disorder
Interventions
Behavioral observation
Other
Lead sponsor
Ohio State University
Other
Eligibility
Up to 10 Days
Enrollment
46 participants
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Mild Cognitive Impairment (MCI), Insomnia, Subjective Cognitive Decline (SCD)
Interventions
Transcranial Magnetic Stimulation (TMS) therapy, Cognitive behavioral therapy for insomnia (CBT-I)
Device · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hematological Malignancy
Interventions
Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma, Brain Tumor
Interventions
Sitagliptin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor, Matched 80 mg placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

Age-dependent Effects of Smoked and Oral Delta-9-THC

NCT05865470
Conditions
Pain, Abuse, Drug, Intoxication; Cannabinoids
Interventions
Cannabis, Dronabinol, Smoked Placebo, Oral Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Obsessive-Compulsive Disorder
Interventions
Dorsal medial Prefrontal Cortex intermittent theta burst stimulation, cTBS to ROFC
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Connection Collective for Older Adults in Subsidized Housing

NCT07863583
Conditions
Social Isolation in Older Adults, Social Isolation or Loneliness, Social Isolation
Interventions
Social Connection Collective: Open-Label Pilot, Social Connection Collective: Pilot
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
62 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Not applicable Interventional

Music for Pain and Dementia

NCT07602283
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions
Drumming session, Music-listening session
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Interventions
MX006
Drug
Lead sponsor
Myricx Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Sarasota, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions
BMS-986504
Drug
Lead sponsor
Ankit Mangla, MD
Other
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Xerostomia
Interventions
D-Limonene Gelcaps, Intensity modulated radiotherapy (IMRT), Cisplatin, Xerostomia questionnaire
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome
Interventions
Nicotinamide Riboside, Pterostilbene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Anastomotic Leaks, Hartmanns Stump Leakage
Interventions
Endo-SPONGE
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Sacramento, California • Orlando, Florida • Weston, Florida + 7 more
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Gastrointestinal Discomfort, Digestive Well Being, Gut-related Symptoms
Interventions
Food ingredient of oyster mushroom mycelium (Pleurotus pulmonarius) and microalgae (Chlorella vulgaris)
Dietary Supplement
Lead sponsor
Koralo GmbH
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy

NCT07122739
Conditions
Healthy
Interventions
Active Real-time fMRI Neurofeedback, Sham Real-time fMRI neurofeedback
Behavioral
Lead sponsor
Trustees of Princeton University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Conditions
Dysphagia, Achalasia, Esophageal, Ineffective Esophageal Motility
Interventions
FLIP, HRM, Prucalopride
Diagnostic Test · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Interventions
PL-14 Allergy Blocker, Ayr® Saline Nasal Mist
Device
Lead sponsor
Polyrizon Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Normal, Illinois • St Louis, Missouri • Ocean City, New Jersey + 2 more
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 9 more
Conditions
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama